



THE
BLADDER CANCER
COMPANY™

Photocure ASA – New share capital registered

Oslo, Norway, 26 June 2020: Reference is made to the previous stock exchange notices where Photocure ASA ("Photocure" or the "Company") announced the allocation of 2,500,000 shares at a subscription price of NOK 76 per share, raising gross proceeds of approx. NOK 190,000,000 in a private placement (the "Private Placement"). The shares will be listed on the Oslo Stock Exchange and are tradeable from today, 26 June 2020.

The share capital increase pertaining to the issuance of the 2,500,000 new shares has now been registered with the Norwegian Register of Business Enterprises. the Company's new registered share capital is 13,305,010.00, divided into 26,610,020 shares, each with a par value of NOK 0.50 per share. Each share represents one vote in the Company's general meeting.

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com, www.cysview.com

This information is subject to the disclosure requirements pursuant to Section 5 -12 the Norwegian Securities Trading Act.

For further information, please contact:

Dan Schneider
President and CEO
Tel: + 1-609 759-6515
Email: ds@photocure.com

Erik Dahl
Chief Financial Officer
Tel: +47 450 55 000
Email: ed@photocure.no